The DOI matches its Crossref record; 77 of the 81 references it cites were found in a registry or an index.
Pharmaceutical industry sponsorship and research outcome and quality: systematic review
Open accessAbstract
OBJECTIVE: To investigate whether funding of drug studies by the pharmaceutical industry is associated with outcomes that are favourable to the funder and whether the methods of trials funded by pharmaceutical companies differ from the methods in trials with other sources of support. METHODS: Medline (January 1966 to December 2002) and Embase (January 1980 to December 2002) searches were supplemented with material identified in the references and in the authors' personal files. Data were independently abstracted by three of the authors and disagreements were resolved by consensus. RESULTS: 30 studies were included. Research funded by drug companies was less likely to be published than research funded by other sources. Studies sponsored by pharmaceutical companies were more likely to have outcomes favouring the sponsor than were studies with other sponsors (odds ratio 4.05; 95% confidence interval 2.98 to 5.51; 18 comparisons). None of the 13 studies that analysed methods reported that studies funded by industry was of poorer quality. CONCLUSION: Systematic bias favours products which are made by the company funding the research. Explanations include the selection of an inappropriate comparator to the product being investigated and publication bias.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“pharmaceutical companies, who fund a substantial number of RCTs, are more likely to seek publication of results with statistically positive outcomes. 9”
From Reporting research results: a moral obligation for all researchers. (2007) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Several investigations show strong associations between the source of funding and the conclusions of research articles [ 219 – 222 ].”
From Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration (2007) · cites this paper as [222]
The cited source says what the claim attributes to it.
In the citing paper
“Empirical evidence points toward funding source sometimes being associated with estimated treatment effects [30].”
From CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials (2010) · cites this paper as [30]
The cited source says what the claim attributes to it.
In the citing paper
“For example, bias, as indicated by a prevalence of more favourable outcomes, has been demonstrated for clinical research funded by industry compared with studies funded by other sources [257–259].”
From Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0 (2020) · cites this paper as [259]
In the citing paper
“Additionally, different outcomes from the same trials can be a source of pharmaceutical marketing bias.35”
In the citing paper
“Lexchin and colleagues [166] observed that outcomes of reports of randomized trials and meta-analyses of clinical trials funded by the pharmaceutical industry are more likely to favor the sponsor's product compared to studies with other sources of funding.”
From The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration (2009) · cites this paper as [166]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration
Altman, D. G., Schulz, K. F., Moher, D., Egger, M., Davidoff, F., Elbourne, D., Gøtzsche, P. C., Lang, T., & for the CONSORT Group (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-8-200104170-00012 · Cited by 3,835
Moher, D., Pham, B., Jones, A., Cook, D. J., Jadad, A. R., Moher, M., Tugwell, P., & Klassen, T. P. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01085-x · Cited by 3,560
Publication bias in clinical research
Easterbrook, P. J., Gopalan, R., Berlin, J. A., & Matthews, D. R. (1991) · The Lancet · doi:10.1016/0140-6736(91)90201-y · Cited by 3,109
Moher, D. (2001) · JAMA · doi:10.1001/jama.285.15.1987 · Cited by 2,545
Hennekens, C. H., Buring, J. E., & Mayrent, S. L. (1987) · Medical Entomology and Zoology · Cited by 2,319
The Hazards of Scoring the Quality of Clinical Trials for Meta-analysis
Jüni, P. (1999) · JAMA · doi:10.1001/jama.282.11.1054 · Cited by 1,981
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-2-316_4 · Cited by 1,938
Scope and Impact of Financial Conflicts of Interest in Biomedical Research: A Systematic Review
Bekelman, J. E., Li, Y., & Gross, C. P. (2003) · JAMA · doi:10.1001/jama.289.4.454 · Cited by 1,816
Moher, D., Schulz, K. F., Altman, D. G., & for the CONSORT Group* (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-8-200104170-00011 · Cited by 1,426
Factors Influencing Publication of Research Results
Dickersin, K. (1992) · JAMA · doi:10.1001/jama.1992.03480030052036 · Cited by 931
Research works printed but not linked: 7
- Djulbegovic, 1999, Violation of the uncertainty principle in conduct of randomized controlled trials (RCTs) of erythropoietin (EPO)., Blood, 94, 399A
- 10.1056/NEJM199304223281612 · DOI
- Wahlbeck, 1999, Sponsored drug trials show more-favourable outcomes., BMJ, 318, 465
- Massie, 1984, Impact of pharmaceutical industry funding of clinical research: results of a survey of antianginal trials., Circulation, 70, 390S
- 10.1001/jama.1997.03540390068038 · DOI
- 10.1001/jama.281.24.2287 · DOI
- 10.1001/jama.1990.03440100121018 · DOI
Cited by
Sorted by citations
Items 501–600 of 1,003
Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis
Martí-Carvajal, A. J., Anand, V., & Solà, I. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010298.pub2 · Cited by 46
Can patents prohibit research? On the social epistemology of patenting and licensing in science
Biddle, J. B. (2014) · Studies in History and Philosophy of Science Part A · doi:10.1016/j.shpsa.2013.12.001 · Cited by 47
Reporting quality of randomized controlled trial abstracts
Hua, F., Deng, L., Kau, C. H., Jiang, H., He, H., & Walsh, T. (2015) · The Journal of the American Dental Association · doi:10.1016/j.adaj.2015.03.020 · Cited by 47
Hendriksma, M., Joosten, M. H. M. A., Peters, J. P. M., Grolman, W., & Stegeman, I. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169316 · Cited by 50
Gómez-García, F., Ruano, J., Gay-Mimbrera, J., Aguilar-Luque, M., Sanz-Cabanillas, J. L., Alcalde-Mellado, P., Maestre-López, B., Carmona-Fernández, P. J., González-Padilla, M., García-Nieto, A. V., et al. (2017) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2017.08.015 · Cited by 37
Norris, S. L., Holmer, H. K., Ogden, L. A., Burda, B. U., & Fu, R. F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075284 · Cited by 46
“There are data suggesting an association between author or funder COI and study outcomes [9-14], between industry relationships and physician behavior [15] or expressed opinions [16,17], and between COI and conclusions in systematic reviews [18].”
BackgroundVedula, S. S., Goldman, P. S., Rona, I. J., Greene, T. M., & Dickersin, K. (2012) · Trials · doi:10.1186/1745-6215-13-136 · Cited by 47
“There is now ample evidence that selective reporting of study results, based on the strength and direction of findings (reporting biases), is widely practiced by the pharmaceutical industry [5,6].”
BackgroundMisinformation in the medical literature: What role do error and fraud play?: Table 1
Steen, R. G. (2011) · Journal of Medical Ethics · doi:10.1136/jme.2010.041830 · Cited by 45
“If a company funds research on a specific medication, then published results tend to favour that product.(8) These findings suggest two plausible interpretations: either the publication is misleading (eg, highlight the good news, bury the bad) or drug makers are clever enough to predict which medications are likely to…”
BackgroundResultThe Global Research Collaboration of Network Meta-Analysis: A Social Network Analysis
Li, L., Catalá-López, F., Alonso‐Arroyo, A., Tian, J., Aleixandre‐Benavent, R., Pieper, D., Ge, L., Yao, L., Wang, Q., & Yang, K. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163239 · Cited by 46
Blinding in Rehabilitation Research
Armijo-Olivo, S. L., Dennett, L., Arienti, C., Dahchi, M., Arokoski, J. P., Heinemann, A. W., & Malmivaara, A. O. V. (2020) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/phm.0000000000001377 · Cited by 47
5-ASA therapy for active Crohn’s disease: Old friends, old data, and a new conclusion
Feagan, B. G. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00121-1 · Cited by 46
Levels of Evidence in Cosmetic Surgery
Swanson, E. C. (2013) · Plastic & Reconstructive Surgery Global Open · doi:10.1097/gox.0000000000000001 · Cited by 45
Sibbald, S. L., Wathen, C. N., Kothari, A. R., & Day, A. M. B. (2013) · Journal of the Medical Library Association JMLA · doi:10.3163/1536-5050.101.2.008 · Cited by 47
“While it was acknowledged that a substantial amount of new information entered the team from pharmaceutical representatives (which resonates with the clinical information seeking or use literature, where a main source of ‘‘evidence’’ is from these commercial vendors [31, 52, 53]), our participants expressed some resis…”
BackgroundBiologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales
Ioannidis, J. P. A., Karassa, F. B., Druyts, E., Thorlund, K., & Mills, E. J. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.134 · Cited by 48
Systematic reviews of meta-analyses: applications and limitations
Delgado‐Rodríguez, M. (2006) · Journal of Epidemiology & Community Health · doi:10.1136/jech.2005.035253 · Cited by 45
Reporting Science and Conflicts of Interest in the Lay Press
Cook, D. M., Boyd, E. A., Grossmann, C., & Bero, L. A. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001266 · Cited by 45
“stock ownership and consulting income) are associated with the reporting of favorable research results and conclusions for the sponsor [13,14,15,16].”
BackgroundSelf-citationNASS Contemporary Concepts in Spine Care: Spinal manipulation therapy for acute low back pain
Dagenais, S., Gay, R. E., Tricco, A. C., Freeman, M., & Mayer, J. M. (2010) · The Spine Journal · doi:10.1016/j.spinee.2010.07.389 · Cited by 47
“The source of funding is an important methodological consideration because of the potential for funding bias [58,59].”
BackgroundKnowledge in the dark: scientific challenges and ways forward
Jeschke, J. M., Lokatis, S., Bartram, I., & Tockner, K. (2019) · FACETS · doi:10.1139/facets-2019-0007 · Cited by 45
The promise and perils of industry‐funded science
Holman, B., & Elliott, K. C. (2018) · Philosophy Compass · doi:10.1111/phc3.12544 · Cited by 88
Antidepressants and benzodiazepines for panic disorder in adults
Bighelli, I., Trespidi, C., Castellazzi, M., Cipriani, A., Furukawa, T. A., Girlanda, F., Guaiana, G., Koesters, M., & Barbui, C. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011567.pub2 · Cited by 50
Jern, P., Johansson, A., Piha, J., Westberg, L., & Santtila, P. O. (2014) · International Journal of Impotence Research · doi:10.1038/ijir.2014.37 · Cited by 44
Treatment Success in Cancer: Industry Compared to Publicly Sponsored Randomized Controlled Trials
Djulbegović, B., Kumar, A., Miladinović, B., Reljic, T., Galeb, S., Mhaskar, A., Mhaskar, R. S., Hozo, I., Tu, D., Stanton, H. A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058711 · Cited by 44
“Previous research has indicated that industry-sponsored trials are usually of better quality than publicly sponsored trials.[5,6] In contrast with the previous research, we found that methodological quality of the CTG trials, with the exception of blinding, were better reported than in GSK trials.”
BackgroundResultInfluentialPearce, W., Raman, S., & Turner, A. J. (2015) · Trials · doi:10.1186/s13063-015-0917-5 · Cited by 44
“There have been a series of systematic reviews over the last 10 years [27–30] demonstrating that industry-funded trials are more likely to have pro-funder results and conclusions.”
BackgroundGonadotrophins for ovulation induction in women with polycystic ovarian syndrome
Weiss, N. S., Nahuis, M. J., Bayram, N., Mol, B. W., van der Veen, F., & van Wely, M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010290.pub2 · Cited by 44
PRIRATE 2020 guidelines for reporting randomized trials in Endodontics: explanation and elaboration
Nagendrababu, V., Duncan, H. F., Bjørndal, L., Kvist, T., Priya, E., Jayaraman, J., Pulikkotil, S. J., & Dummer, P. M. H. (2020) · International Endodontic Journal · doi:10.1111/iej.13304 · Cited by 44
Wandall, B., Hansson, S. O., & Rudén, C. (2007) · Archives of Toxicology · doi:10.1007/s00204-007-0194-5 · Cited by 44
“Many of these studies demonstrate a signiWcant bias in reported and published results (see e.g., Bekelman et al. 2003; Dickersin 1997; Kaptchuk 2003; Lexchin et al. 2003 ).”
ResultThe Proliferation of Clinical Practice Guidelines: Professional Development or Medicine-by-Numbers?
Genuis, S. J. (2005) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.18.5.419 · Cited by 41
“In fact, specific drugs being researched are recommended as the treatment of choice 3 times more often if the research is funded by a for-profit versus a nonprofit organization.(40) Researchers supported by industry are often required to sign confidentiality agreements or “gag clauses” limiting their freedom to dissem…”
BackgroundFinancial conflicts of interest in psychiatry.
Fava, G. A. (2007) · PubMed Central · Cited by 44
Homoeopathy and “the growth of truth”
Vandenbroucke, J. P. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67151-6 · Cited by 44
Manchikanti, L. (2008) · Pain Physician · doi:10.36076/ppj.2008/11/271 · Cited by 76
Human recombinant activated protein C for severe sepsis
Martí-Carvajal, A. J., Solà, I., Lathyris, D., & Cardona, A. F. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004388.pub4 · Cited by 44
Pharmacological interventions for apathy in Alzheimer's disease
Ruthirakuhan, M. T., Herrmann, N., Abraham, E. H., Chan, S., & Lanctôt, K. L. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012197.pub2 · Cited by 113
Commercial Interests and the Erosion of Trust in Science
Pinto, M. F. (2020) · Philosophy of Science · doi:10.1086/710521 · Cited by 50
“dustry bias in the results of the former but no bias in the latter (Lexchin et al. 2003).”
BackgroundResultInfluentialTsai, A. C., Rosenlicht, N. Z., Jureidini, J. N., Parry, P. I., Spielmans, G. I., & Healy, D. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000434 · Cited by 43
“However, financial conflicts of interest have been found to be associated with biased reporting of outcomes in randomized trials [115,116], which serve as the evidence upon which treatment guideline recommendations are based.”
Alzheimer’s Disease Dementia Guidelines for Diagnostic Testing
Arévalo-Rodríguez, I., Pedraza, O. L., Rodríguez, A., Sánchez, E., Gich, I. J., Solà, I., Bonfill, X., & Alonso‐Coello, P. (2013) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317512470209 · Cited by 43
Conflicts of interest at the European Food Safety Authority erode public confidence
Robinson, C., Holland, N., Leloup, D., & Muilerman, H. (2013) · Journal of Epidemiology & Community Health · doi:10.1136/jech-2012-202185 · Cited by 42
Academic Influence and Its Relationship to Industry Payments in Orthopaedic Surgery
Buerba, R. A., Sheppard, W. L., Herndon, K. E., Gajewski, N. D., Patel, A. D., Leong, N. L., Bernthal, N. M., & SooHoo, N. F. (2018) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.17.00838 · Cited by 43
Rahman, E., Alhitmi, H. K., & Mosahebi, A. (2021) · Aesthetic Surgery Journal · doi:10.1093/asj/sjab058 · Cited by 43
Misconduct by researchers and authors
Marcovitch, H. (2007) · Gaceta Sanitaria · doi:10.1157/13112245 · Cited by 43
Modelling Disease Progression in??Alzheimer???s Disease
Green, C. (2007) · PharmacoEconomics · doi:10.2165/00019053-200725090-00003 · Cited by 44
Aligning physiology with psychology: Translational neuroscience in neuropsychiatric drug discovery
McArthur, R. A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.02.004 · Cited by 42
Search strategies to identify information on adverse effects: a systematic review
Golder, S., & Loke, Y. K. (2009) · Journal of the Medical Library Association JMLA · doi:10.3163/1536-5050.97.2.004 · Cited by 42
Ali, A., Weiss, T. R., McKee, D., Scherban, A., Khan, S., Fields, M. R., Apollo, D., & Mehal, W. Z. (2017) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2017-000164 · Cited by 42
“This study was designed, conducted, and analysed completely independent of the sponsor, 36 and preregistered on ClincialTrials. gov .”
MethodEffect Sizes, Power, and Biases in Intelligence Research: A Meta-Meta-Analysis
Nuijten, M. B., van Assen, M. A. L. M., Augusteijn, H. E. M., Crompvoets, E. A. V., & Wicherts, J. M. (2020) · Journal of Intelligence · doi:10.3390/jintelligence8040036 · Cited by 42
The cost-effectiveness of drug-eluting stents: a systematic review
Ligthart, S. A., Vlemmix, F., Dendukuri, N., & Brophy, J. M. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.061020 · Cited by 42
Rosenheck, R. A. (2007) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.106.035063 · Cited by 42
“…have also suggested that industry-sponsored studies of second-generation antipsychotics are especially likely to favour the manufacturers’ product (Montgomery et al, 2004; Heres et al, 2006), a phenomenon familiar in other areas of medicine as well (Bekelman et al, 2003; Lexchin et al, 2003).”
BackgroundGallo, M. F., Nanda, K., Grimes, D. A., & Schulz, K. F. (2005) · Contraception · doi:10.1016/j.contraception.2004.09.005 · Cited by 42
de Oliveira, G. S., & Baggs, E. (2023) · Cambridge University Press eBooks · doi:10.1017/9781009303538 · Cited by 57
“569), as well as when comparing results of studies funded by different commercial sponsors (see Bekelman, Li, and Gross, 2003; Lexchin et al., 2003).”
ResultBariani, G. M., Ferrari, A. C. R. D. C., Hoff, P. M., Krzyzanowska, M. K., & Riechelmann, R. P. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.6706 · Cited by 41
“The growing participation of the pharmaceutical industry in medical research has influenced the interpretation of study results toward favoring experimental therapy.(19,20) In oncology, previous studies demonstrated a positive association between COI of authors and favorable opinion toward the investigational therapy…”
ResultBbosa, G. S., Wong, G., Kyegombe, D. B., & Ogwal-Okeng, J. W. (2014) · Health · doi:10.4236/health.2014.62027 · Cited by 47
“They were used to avoid publication bias [50-55].”
MethodAssociation Between Research Sponsorship and Study Outcome in Plastic Surgery Literature
Momeni, A., Becker, A., Bannasch, H., Antes, G., Blümle, A., & Stark, G. B. (2009) · Annals of Plastic Surgery · doi:10.1097/sap.0b013e3181951917 · Cited by 45
“A statistically significant association between industry funding and trial conclusions in medical RCTs has been demonstrated by several studies.(8,17,18) A meta-analysis of 1140 pooled original articles conducted by Bekelman et al verified a statistically significant association between industry sponsorship and pro-in…”
ResultCONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials
Lee, J. S., Ahn, S., Lee, K. H., Kim, J. H., Schulz, K. F., Altman, D. G., & Moher, D. (2014) · Epidemiology and Health · doi:10.4178/epih/e2014029 · Cited by 44
“추정된 치료효과가 연구비와 연관되어 있음을 경험적 증거들이 보여주고 있다 [30].”
From clinical trials of antiepileptic drugs to treatment
Perucca, E. (2018) · Epilepsia Open · doi:10.1002/epi4.12239 · Cited by 41
“A more insidious way to generate data useful for drug promotion consists of conducting RCTs that incorporate bias favoring the sponsor’s product.(1,2,59,60) These bias can affect any aspect of a trial design, from the choice of eligibility criteria to the interpretation of the results (Table 2).”
MethodViewpoint: the elephant in medical professionalism's kitchen.
Hafferty, F. (2006) · Academic medicine : journal of the Association of American Medical Colleges · doi:10.1097/01.acm.0000238230.80419.cf · Cited by 43
Vitiello, B., Heiligenstein, J. H., Riddle, M. A., Greenhill, L. L., & Fegert, J. M. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.03.011 · Cited by 41
Editorial bias in scientific publications
Matías‐Guiu, J., & García-Ramos, R. (2011) · Neurología (English Edition) · doi:10.1016/s2173-5808(11)70001-3 · Cited by 43
Institutional Conflicts of Interest in Academic Research
Resnik, D. B. (2019) · Science and Engineering Ethics · doi:10.1007/s11948-015-9702-9 · Cited by 40
“There is a sizeable body of evidence demonstrating that sources of funding and investigator’s financial interests can influence research outcomes (Friedberg et al. 1999; Krimsky 2003; Lexchin et al. 2003; Resnik 2007; Ridker and Torres 2006; Sismondo 2008; Stelfox et al. 1998).”
Randomized clinical trials: what gets published, and when?
Hirsch, L. (2004) · Europe PMC (PubMed Central) · Cited by 39
Massey, P. R., Wang, R., Prasad, V. K., Bates, S. E., & Fojo, T. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0516 · Cited by 41
Boyd, E. A., Akl, E. A., Baumann, M. H., Curtis, J. R., Field, M. J., Jaeschke, R., Osborne, M. L., & Schünemann, H. J. (2012) · Proceedings of the American Thoracic Society · doi:10.1513/pats.201208-057st · Cited by 40
Brennan, R., Eagle, L. C., & Rice, D. A. (2009) · Journal of Macromarketing · doi:10.1177/0276146709352221 · Cited by 38
“Lexchin et al. (2003) found that industry-funded research had as good, if not better, methodological quality than nonindustry-funded research.”
BackgroundEfficacy and harms of the hypoglycemic agent pramlintide in diabetes mellitus
Lee, N. J., Norris, S. L., & Thakurta, S. (2010) · The Annals of Family Medicine · doi:10.1370/afm.1174 · Cited by 39
Evidence-based medicine in China
Wang, J. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62131-0 · Cited by 39
Pharmaceutical Industry Marketing: Understanding Its Impact on Women’s Health
Sufrin, C., & Ross, J. S. (2008) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0b013e31817f1585 · Cited by 39
“lized as subtly cloaked marketing tools (87).”
Asking the Oracle: Introducing Forecasting Principles into Agent-Based Modelling
Hassan, S., Arroyo, J., Galán, J. M., Antunes, L., & Pavón, J. (2013) · Journal of Artificial Societies and Social Simulation · doi:10.18564/jasss.2241 · Cited by 39
“There is multiple evidence of the likelihood of such bias: Lexchin (2003) study pharmaceutical industry sponsorship in research and conclude that ''systematic bias favours products which are made by the company funding the research''; Lesser et al. (2007) study the nutrition-related scientific…”
BackgroundThe Impact of Conflict of Interest in Abdominal Wall Reconstruction With Acellular Dermal Matrix
DeGeorge, B. R., Holland, M. C., & Drake, D. B. (2015) · Annals of Plastic Surgery · doi:10.1097/sap.0000000000000372 · Cited by 39
Gómez-García, F. J., Ruano, J., Aguilar-Luque, M., Gay-Mimbrera, J., Maestre-López, B., Sanz-Cabanillas, J. L., Carmona-Fernández, P. J., González-Padilla, M., García-Nieto, A. J. V., & Isla-Tejera, B. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15380 · Cited by 39
A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
Peter, W. L. S., Wazny, L. D., Weinhandl, E. D., Cardone, K. E., & Hudson, J. Q. (2017) · Drugs · doi:10.1007/s40265-017-0758-5 · Cited by 38
Tan, C., Zhao, Y., & Wang, S. (2019) · Critical reviews in food science and nutrition · doi:10.1080/10408398.2018.1461062 · Cited by 32
“Existing research indicated that publication results may favor the sponsor’s product (Lexchin et al. 2003).”
BackgroundPahus, L., Suehs, C., Halimi, L., BOURDIN, A. A., Chanez, P., Jaffuel, D., Marciano, J., Gamez, A. S., Vachier, I., & Molinari, N. (2020) · BMC Medical Ethics · doi:10.1186/s12910-020-00509-y · Cited by 39
Use of ketamine and esketamine for depression: an overview of systematic reviews with meta-analyses
Lima, T. D. M., Visacri, M. B., & Aguiar, P. M. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03216-8 · Cited by 43
Johansson, I., & Lynöe, N. (2008) · De Gruyter eBooks · doi:10.1515/9783110321364 · Cited by 56
Galvin, I. M., Steel, A. C., Pinto, R. L., Ferguson, N. D., & Davies, M. W. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003707.pub3 · Cited by 39
Colombo, C., Mosconi, P., Villani, W., & Garattini, S. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034974 · Cited by 39
Soft Targets: Nurses and the Pharmaceutical Industry
Jutel, A., & Menkes, D. B. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050005 · Cited by 39
Triphasic versus monophasic oral contraceptives for contraception
Vliet, H. A. V., Grimes, D. A., Lopez, L. M., Schulz, K. F., & Helmerhorst, F. M. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003553.pub3 · Cited by 39
Gagnier, J. J., Moher, D., Boon, H. S., Beyene, J., & Bombardier, C. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.10.005 · Cited by 38
Roundtree, A. K., Kallen, M. A., Lopez-Olivo, M. A., Kimmel, B., Skidmore, B., Ortiz, Z., Cox, V., & Suarez-Almazor, M. E. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2008.08.003 · Cited by 38
Andrade, N. S., Flynn, J. P., & Bartanusz, V. (2013) · The Spine Journal · doi:10.1016/j.spinee.2013.06.071 · Cited by 38
“As in other fields of medicine [79–82], the influence of financial interests on research conclusions in spine surgery appears to be substantial.”
BackgroundInsulin therapy in type 2 diabetes: what is the evidence?
van Avendonk, M. J. P., & Rutten, G. E. H. M. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00981.x · Cited by 38
Alasbali, T. A., Smith, M. R., Geffen, N., Trope, G. E., Flanagan, J. G., Jin, Y.-P., & Buys, Y. M. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2008.07.005 · Cited by 38
O’Donohoe, T. J., Dhillon, R., Bridson, T. L., & Tee, J. (2018) · Neurosurgery · doi:10.1093/neuros/nyy615 · Cited by 39
L’évaluation et l’efficacité des psychothérapies psychanalytiques et de la psychanalyse
Rabeyron, T. (2020) · L Évolution Psychiatrique · doi:10.1016/j.evopsy.2020.07.003 · Cited by 43
Chou, R. (2008) · Pain Medicine · doi:10.1111/j.1526-4637.2008.00422_1.x · Cited by 38
Doran, E., Kerridge, I., McNeill, P. M., & Henry, D. A. (2005) · Social Science & Medicine · doi:10.1016/j.socscimed.2005.07.037 · Cited by 38
Premature ejaculation and pharmaceutical company-based medicine: the dapoxetine case.
Waldinger, M., & Schweitzer, D. (2008) · Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2008.00633.x · Cited by 33
Genuis, S., & Genuis, S. (2006) · Journal of Evaluation In Clinical Practice · doi:10.1111/j.1365-2753.2005.00608.x · Cited by 43
Ethics and the global financial crisis: why incompetence is worse than greed
(2015) · Choice Reviews Online · doi:10.5860/choice.190703 · Cited by 38
Bassler, D., Mueller, K. F., Briel, M., Kleijnen, J., Marušić, A., Wager, E., Antes, G., von Elm, E. B., Altman, D. G., & Meerpohl, J. J. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010024 · Cited by 36
Pinto, M. F. (2020) · Frontiers in Research Metrics and Analytics · doi:10.3389/frma.2020.588331 · Cited by 46
Accounting for uncertainty about investigator bias: disclosure is informative
Greenland, S. (2009) · Journal of Epidemiology & Community Health · doi:10.1136/jech.2008.084913 · Cited by 37
Norris, S. L., Holmer, H. K., Ogden, L. A., Burda, B. U., & Fu, R. F. (2012) · BMC Medical Ethics · doi:10.1186/1472-6939-13-24 · Cited by 37
“In addition, both funder and author conflicts are associated with bias in the results of research studies [3-7] and derivative products such as systematic reviews [8] and clinical practice guidelines [9].”
BackgroundGorman, D. M., & Conde, E. (2007) · Evaluation and Program Planning · doi:10.1016/j.evalprogplan.2007.06.004 · Cited by 38
Not all that glitters is gold: A guide to the critical interpretation of drug trials in epilepsy
Perucca, E., & Wiebe, S. (2016) · Epilepsia Open · doi:10.1002/epi4.3 · Cited by 37
The Effectiveness of Pharmaceutical Marketing
Kappe, E. (2006) · RePub (Erasmus University Rotterdam) · Cited by 37
Human recombinant activated protein C for severe sepsis
Martí-Carvajal, A. J., Salanti, G., & Cardona, A. F. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004388.pub3 · Cited by 37
Krauth, D., Anglemyer, A., Philipps, R., & Bero, L. (2014) · PLoS Biology · doi:10.1371/journal.pbio.1001770 · Cited by 36
“Industry sponsorship biases the written research record towards outcomes that are favorable to the sponsor, even when controlling for study design criteria [10–16].”
BackgroundSelf-citationConflict of interest in oncology publications
Kesselheim, A. S., Lee, J. L.-Y., Avorn, J., Servi, A. D., Shrank, W. H., & Choudhry, N. K. (2011) · Cancer · doi:10.1002/cncr.26237 · Cited by 36
Impact of Funding Source on Clinical Trial Results Including Cardiovascular Outcome Trials
Riaz, H., Raza, S., Khan, M. S., Riaz, I. B., & Krasuski, R. A. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.09.034 · Cited by 36
The Ultimate Goal of Prevention and the Larger Context for Translation
Biglan, A. (2016) · Prevention Science · doi:10.1007/s11121-016-0635-6 · Cited by 40
Metadata
- Authors
- Lexchin, J., Bero, L. A., Djulbegovic, B., & Clark, O.
- Affiliations
- York University (CA)
- University of California, San Francisco (US)
- Corresponding author
- Lexchin, Joel
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2003-05-29
- Volume
- 326
- Issue
- 7400
- Pages
- 1167-1170
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- PMC
- PMC156458
- OpenAlex
- W2136284733
- Cited by
- 2,147
- References
- 81
- Citations by year
- 2026: 34 · 2025: 49 · 2024: 61 · 2023: 56 · 2022: 57 · 2021: 53 · 2020: 89 · 2019: 74 · 2018: 86 · 2017: 84 · 2016: 82 · 2015: 100 · 2014: 114 · 2013: 107 · 2012: 150
- FWCI
- 10.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.bmj.com/company/legal-information/terms-conditions/legal-information/tdm-licencepolicy (tdm)
- Locations
- BMJ (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- DigitalGeorgetown (Georgetown University Library) (submittedVersion)
- Topics
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Global Public Health Policies and Epidemiology
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Keywords
- pharmaceutical industry sponsorship, research bias, publication bias, trial quality, research funding sources, comparator selection, conflicts of interest
- MeSH terms
- Clinical Trials as Topic, Drug Industry, Financing, Organized, Publishing, Research, Research Support as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
